Trial
NCT03994783
Transplant Antibody-Mediated Rejection: Guiding Effective Treatments
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Imperial College London
Collaborators
Cambridge University Hospitals NHS Foundation Trust; National Institute for Health Research, United Kingdom; Kidney Cancer UK
Condition
Kidney Transplant Rejection
Intervention
Rituximab
Why stopped
Stopped at start of COVID-19 pandemic - non-feasible
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-04-13